• 03/27/2021 13:43

    ​​​​​​​PAION RECEIVES EUROPEAN COMMISSION APPROVAL OF BYFAVO(R) (REMIMAZOLAM) FOR PROCEDURAL SEDATION

  • 03/19/2021 20:13

    PAION AG TO ISSUE APPROX. 5 MILLION SHARES AT EUR 1.54 PER SHARE IN CAPITAL INCREASE WITH SUBSCRIPTION RIGHTS

  • 01/29/2021 11:20

    ​​​​​​​PAION RECEIVES POSITIVE CHMP OPINION RECOMMENDING APPROVAL OF BYFAVO(R) (REMIMAZOLAM) IN PROCEDURAL SEDATION

  • 01/12/2021 13:40

    ​​​​​​​PAION ANNOUNCES EXCLUSIVE LICENSING AGREEMENT WITH LA JOLLA PHARMACEUTICAL FOR GIAPREZA(TM) (ANGIOTENSIN II) AND XERAVA(TM) (ERAVACYCLINE) IN EUROPE

  • 01/07/2021 11:14

    PAION AG: HANA PHARM RECEIVES MARKET APPROVAL FOR REMIMAZOLAM (BYFAVO) IN GENERAL ANESTHESIA IN SOUTH KOREA